Taxpayers are subsidizing 80 percent of Regeneron’s COVID-19 treatment’s R&D costs
Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading